Antibiotics have drastically reduced mortality associated with infectious diseases. Yet, their effectiveness and easy access led to misuse and overuse, prompting bacteria to develop resistance. Currently, antibiotics usually target essential pathways, therefore inhibiting a broad spectrum of bacteria and increasing the risk of resistance development leading to dramatic health issues. Thus, new antibacterials are urgently needed. A major challenge for efficient drug design is to identify appropriate targets. This project focuses on the characterization of two original bacterial targets, the mutation frequency decline protein (Mfd) and the nicotinamide adenosine dinucleotide kinase (NADK), and their inhibition by novel molecules.